{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:42:01Z","timestamp":1790829721182,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006704","name":"University of Ostrava","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To estimate the timepoint of onset of the lower urinary tract symptoms (LUTS) over the course of multiple sclerosis (MS), determine which of the LUTS typically appears first, and identify risk factors for early development of LUTS in patients with MS (PwMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study included 1167 PwMS. The participants were predominantly women (72%), median age was 45 (IQR 36;53) years, and median disease duration was 11 (IQR 6;16) years. Inclusion criteria were age over 18 years, proven MS diagnosis according to McDonald\u00b4s criteria (2017), and complete medical records since establishment of MS diagnosis. A structured in-person interview addressing the study objectives was performed during routine follow-up visit. The data were cross-checked with the medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median LUTS-free survival time after MS diagnosis has been made, was 8 (IQR 7;10) years. Storage, voiding and postmicturition symptoms were identified as a first LUTS in 549\/709 (77%), 130\/709 (18%), and 30\/709 (4.2%) PwMS, respectively. Most frequently reported first LUTS was urgency 360 (51%). Using multivariate analysis, higher age, higher degree of disability, and presence of cerebellar and\/or pyramidal symptoms at the time of MS diagnosis were significantly associated with shorter LUTS-free survival. No significant relationship between LUTS-free survival and sex or type of MS was found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data show, that LUTS occur after median time of 8 years after MS diagnosis, with urgency being the most frequently reported first LUTS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05709-y","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:24:29Z","timestamp":1748676269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of the onset of lower urinary tract symptoms in multiple scleroris patients"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-5926","authenticated-orcid":false,"given":"Jan","family":"Krhut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Hrad\u00edlek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e9la","family":"Kond\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Skugarevsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Woznicov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek Paus","family":"S\u00fdkora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Kobber\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Rychl\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"14","key":"5709_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler 26(14):1816\u20131821","journal-title":"Mult Scler"},{"key":"5709_CR2","doi-asserted-by":"publisher","first-page":"1448377","DOI":"10.3389\/fneur.2024.1448377","volume":"15","author":"S Safiri","year":"2024","unstructured":"Safiri S, Ghaffari Jolfayi A, Mousavi SE, Nejadghaderi SA, Sullman MJM, Kolahi AA (2024) Global burden of multiple sclerosis and its attributable risk factors, 1990\u20132019. Front Neurol 15:1448377","journal-title":"Front Neurol"},{"key":"5709_CR3","first-page":"412","volume":"14","author":"H Oppenheim","year":"1889","unstructured":"Oppenheim H (1889) Weitere notizen Zur pathologie der disseminierten sklerose. Charit\u00e9-Ann 14:412\u2013418","journal-title":"Charit\u00e9-Ann"},{"issue":"4","key":"5709_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/135245850100700404","volume":"7","author":"MW Nortvedt","year":"2001","unstructured":"Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI (2001) Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 7(4):231\u2013235","journal-title":"Mult Scler"},{"key":"5709_CR5","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.msard.2020.102378","volume":"45","author":"M Monti Bragadin","year":"2020","unstructured":"Monti Bragadin M, Motta R, Messmer Uccelli M et al (2020) Lower urinary tract dysfunction in patients with multiple sclerosis: A post-void residual analysis of 501 cases. Mult Scler Relat Disord 45:102378","journal-title":"Mult Scler Relat Disord"},{"key":"5709_CR6","doi-asserted-by":"publisher","first-page":"205031212311780","DOI":"10.1177\/20503121231178047","volume":"11","author":"F Sharifiaghdas","year":"2023","unstructured":"Sharifiaghdas F, Narouie B, Taheri M et al (2023) Multiple sclerosis and lower urinary tract symptoms: A survey of prevalence, characteristic and urological evaluations. SAGE Open Med 11:20503121231178047","journal-title":"SAGE Open Med"},{"issue":"3","key":"5709_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1590\/S1677-55382009000300009","volume":"35","author":"B Onal","year":"2009","unstructured":"Onal B, Siva A, Buldu I, Demirkesen O, Cetinel B (2009) Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol 35(3):326\u2013333","journal-title":"Int Braz J Urol"},{"issue":"1","key":"5709_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12883-019-1582-1","volume":"20","author":"F Nazari","year":"2020","unstructured":"Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V (2020) The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis. BMC Neurol 20(1):24","journal-title":"BMC Neurol"},{"issue":"7624","key":"5709_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806\u2013808","journal-title":"BMJ"},{"issue":"2","key":"5709_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"11","key":"5709_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"key":"5709_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5489\/cuaj.4058","volume":"11","author":"SM Aharony","year":"2017","unstructured":"Aharony SM, Lam O, Corcos J (2017) Evaluation of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can Urol Assoc J 11:61\u201364","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"5709_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0022-5347(17)49710-2","volume":"132","author":"SA Awad","year":"1984","unstructured":"Awad SA, Gajewski JB, Sogbein SK, Murray TJ, Field CA (1984) Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 132(3):499\u2013502","journal-title":"J Urol"},{"key":"5709_CR14","doi-asserted-by":"publisher","first-page":"102248","DOI":"10.1016\/j.msard.2020.102248","volume":"44","author":"B Domurath","year":"2020","unstructured":"Domurath B, Kurze I, Kirschner-Hermanns R et al (2020) Neurourological assessment in people with multiple sclerosis (MS): a new evaluated algorithm. Mult Scler Relat Disord 44:102248","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"5709_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.juro.2009.12.029","volume":"183","author":"ST Mahajan","year":"2010","unstructured":"Mahajan ST, Patel PB, Marrie RA (2010) Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS patient registry. J Urol 183(4):1432\u20131437","journal-title":"J Urol"},{"issue":"3","key":"5709_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/jnnp.56.3.245","volume":"56","author":"CD Betts","year":"1993","unstructured":"Betts CD, D\u2019Mellow MT, Fowler CJ (1993) Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56(3):245\u2013250","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"5709_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1177\/1352458506075651","volume":"13","author":"M de S\u00e8ze","year":"2007","unstructured":"de S\u00e8ze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13(7):915\u2013928","journal-title":"Mult Scler"},{"issue":"1","key":"5709_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/nau.22670","volume":"35","author":"KM Khalaf","year":"2016","unstructured":"Khalaf KM, Coyne KS, Globe DR et al (2016) The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. Neurourol Urodyn 35(1):48\u201354","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5709_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/1352458516633903","volume":"22","author":"V Ph\u00e9","year":"2016","unstructured":"Ph\u00e9 V, Pakzad M, Curtis C et al (2016) Urinary tract infections in multiple sclerosis. Mult Scler 22(7):855\u2013861","journal-title":"Mult Scler"},{"issue":"3","key":"5709_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278\u2013286","journal-title":"Neurology"},{"key":"5709_CR21","volume-title":"EAU guidelines on Neuro-Urology","author":"B Blok","year":"2025","unstructured":"Blok B, Castro-Diaz D, del Popolo G et al (2025) EAU guidelines on Neuro-Urology. European Assotiation of Urology Guidelines Office, Arnhem"},{"issue":"5","key":"5709_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrurol.2016.53","volume":"13","author":"V Ph\u00e9","year":"2016","unstructured":"Ph\u00e9 V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13(5):275\u2013288","journal-title":"Nat Rev Urol"},{"issue":"4","key":"5709_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1097\/01.ju.0000049644.27713.c8","volume":"169","author":"I Araki","year":"2003","unstructured":"Araki I, Matsui M, Ozawa K, Takeda M, Kuno S (2003) Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 169(4):1384\u20131387","journal-title":"J Urol"},{"issue":"Suppl 1","key":"5709_CR24","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.5213\/inj.2142012.006","volume":"26","author":"K Tran","year":"2022","unstructured":"Tran K, Hubbard L, Karmonik C, Boone TB, Khavari R (2022) Preliminary analysis of brain footprints in multiple sclerosis females with detrusor sphincter dyssynergia: A concurrent urodynamic and functional magnetic resonance imaging study. Int Neurourol J 26(Suppl 1):S38\u201346","journal-title":"Int Neurourol J"},{"issue":"2","key":"5709_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/nau.22953","volume":"36","author":"SJ Weissbart","year":"2017","unstructured":"Weissbart SJ, Pechersky D, Malykhina A et al (2017) The impact of Pontine disease on lower urinary tract symptoms in patients with multiple sclerosis. Neurourol Urodyn 36(2):453\u2013456","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"5709_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7224\/1537-2073.2019-030","volume":"22","author":"HB Al Dandan","year":"2020","unstructured":"Al Dandan HB, Coote S, McClurg D (2020) Prevalence of lower urinary tract symptoms in people with multiple sclerosis: A systematic review and Meta-analysis. Int J MS Care 22(2):91\u201399","journal-title":"Int J MS Care"},{"issue":"2","key":"5709_CR27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/nau.24276","volume":"39","author":"J Medina-Polo","year":"2020","unstructured":"Medina-Polo J, Adot JM, Allu\u00e9 M et al (2020) Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. Neurourol Urodyn 39(2):762\u2013770","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5709_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/ene.13010","volume":"23","author":"C Zecca","year":"2016","unstructured":"Zecca C, Riccitelli GC, Disanto G et al (2016) Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients\u2019 quality of life. Eur J Neurol 23(7):1228\u20131234","journal-title":"Eur J Neurol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05709-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05709-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:51:41Z","timestamp":1767966701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05709-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05709-y","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JK: consultant for Coloplast, Medtronic, Promedon, and Stimvia; PH: consultant for Biogen Idec, Novartis, Merck, Roche, Sanofi Genzyme, Teva, Bristol Meyer Squibb, and Janssen Cilag; HK: consultant for Medtronic; AK, BS, IW, RPS, TR, and PZ: nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"342"}}